Key facts
- This page summarizes Andrew John Partridge's Form 4 filing for Turning Point Therapeutics, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Feb 2022, 17:09.
Andrew John Partridge - 09 Feb 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc.
- Reporting relationship
- EVP & Chief Commercial Officer
- Issuer ticker
- N/A
- Reported as of
- 09 Feb 2022
- Net transaction value
- -$8,022
- SEC form
- 4
- Accepted by SEC
- 11 Feb 2022, 17:09:59 UTC
- Prior SEC filing
- 15 Jul 2021
- Next SEC filing
- 02 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paolo Tombesi, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrew John Partridge filed Form 4 for Turning Point Therapeutics, Inc. on 11 Feb 2022.
Change
- Previous filing in this sequence was filed on 15 Jul 2021.
- Current net transaction value: -$8,022.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TPTX
transaction
Common Stock
Sale
- Transaction value
- $8,022
- Shares
- -221
- Change %
- -0.99%
- Price
- $36.30
- Shares after
- 22,078
- Date
- 09 Feb 2022
- Ownership
- Direct
- Footnotes
- F1, F2
TPTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +16,283
- Change %
- +74%
- Price
- $0.000000
- Shares after
- 38,361
- Date
- 09 Feb 2022
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TPTX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +58,600
- Change %
- Price
- $0.000000
- Shares after
- 58,600
- Date
- 09 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 58,600
- Exercise price
- $37.68
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
Footnote F2
The Reporting Person acquired 199 shares on June 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 333 shares on December 10, 2021 pursuant to the ESPP.
Footnote F3
Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
Footnote F4
1/48th of the shares vest monthly following February 9, 2022.